InMed Pharmaceuticals Inc. 8-K

What Happened
InMed Pharmaceuticals Inc. (INM) filed an Form 8-K on March 6, 2026, disclosing that the board ratified BayMedica LLC’s decision to wind down and exit its commercial operations. BayMedica is a wholly owned subsidiary and represents the company’s only revenue-generating commercial segment. The decision follows provisions in H.R. 5371 (the “Act”) that, if effective as planned on November 12, 2026, would materially and negatively affect BayMedica’s commercial business and its inventory of certain rare, non‑intoxicating cannabinoids. The board approved the wind down on March 4, 2026; BayMedica expects to substantially complete the exit before its fiscal year end on June 30, 2026.

Key Details

• BayMedica will continue sales, marketing, limited manufacturing, and logistics during the wind-down period but aims to cease commercial operations by June 30, 2026.
• Estimated exit-related cash costs: about $550,000 for severance and employee-related costs, plus approximately $120,000 of additional related expenditures (total ≈ $670,000).
• These estimated costs are expected to be offset in part by profits from product sales during the wind-down; actual amounts and timing may differ materially.
• After the wind down, InMed will focus exclusively on developing its pharmaceutical pipeline, including INM-901 (Alzheimer’s disease) and INM-089 (dry AMD) toward IND filings and initial human trials.

Why It Matters
For investors, this is a material strategic and financial change: InMed is exiting its only current revenue-generating commercial business, which could reduce near-term revenue but also limits continued operational exposure to regulatory changes under H.R. 5371. The company estimates modest one-time cash exit costs (~$670K), but warns actual charges could be higher. Going forward, InMed’s value proposition will rest on its pharmaceutical pipeline and progress toward IND filings and clinical trials rather than product sales.